文献速递湿疹皮炎与荨麻疹

Tralokinumab治疗特应性皮炎诱导渐进性转录组反应

Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response.
PubMed 文献 · J Invest Dermatol · 2024-12-27

该前瞻性研究对16例中重度特应性皮炎患者基线和第2、16周皮损活检行RNA测序,评估IL-13抑制剂tralokinumab对皮肤转录组的影响。治疗诱导早期和延迟基因表达变化,使皮损转录组逐渐向非皮损皮肤转变,但第16周仍有751个基因与健康对照皮肤显著失调。

要点

  • Tralokinumab可调节角质形成细胞增殖分化、瘙痒信号及下游炎症反应相关基因。
  • 皮损转录组在治疗第2周和第16周呈渐进性改善,向非皮损皮肤转变。
  • 第16周仍有751个基因显著失调,提示中重度特应性皮炎需长期免疫调节治疗。

核心结论

  • Tralokinumab治疗特应性皮炎诱导早期和延迟的转录组变化,使皮损转录组逐渐向非皮损皮肤转变。
  • 第16周仍有751个基因与健康对照皮肤相比显著失调,支持中重度特应性皮炎需长期免疫调节治疗以实现深度应答。

研究设计与样本

  • 前瞻性研究,对16例中重度特应性皮炎患者基线和第2、16周皮损活检行RNA测序分析。
  • 研究注册于ClinicalTrials.gov(NCT04556461)。

主要发现

  • Tralokinumab治疗诱导早期和延迟的基因表达变化。
  • 治疗调节角质形成细胞增殖与分化、瘙痒信号及下游炎症反应相关基因。
  • 第16周皮损转录组向非皮损皮肤转变,但仍有751个基因与健康对照皮肤显著失调。

临床怎么用

  • Tralokinumab通过IL-13抑制多维度改善特应性皮炎皮肤转录组异常。
  • 中重度特应性皮炎需长期免疫调节治疗以追求深度应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atopic dermatitis is characterized by a complex epidermal barrier deficiency and exaggerated immune responses dominated by type 2 mechanisms with variable contributions of additional immune axes. IL-13 is overexpressed in atopic dermatitis skin and a key driver of both barrier dysfunction and inflammation. In this study, we prospectively studied the effects of IL-13 inhibition with tralokinumab on cutaneous transcriptome profiles using RNA sequencing of biopsies from 16 patients with moderate-to-severe atopic dermatitis obtained at baseline, week 2, and week 16. Tralokinumab therapy induced early and delayed expression changes and progressively shifted the transcriptomic profile of lesional toward nonlesional skin by modulating both genes associated with keratinocyte proliferation and differentiation, itch signaling, and downstream inflammatory responses. At week 16, 751 genes were still significantly dysregulated compared with those in healthy control skin, reinforcing the need for long-term immunomodulatory therapy of moderate-to-severe atopic dermatitis to achieve deep responses. The study was registered with ClinicalTrials.gov (NCT04556461).

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Tandon R, Harder I, Stölzl D, et al. Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response. J Invest Dermatol. 2024. PMID: 39733934. doi:10.1016/j.jid.2024.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。